

Summary: Immunotherapy in digestive cancers - Where are we heading?

Tamara Matysiak-Budnik

UEG Postgraduate Teaching Programme Berlin 2025

Presentation

Digestive Oncology

Immunology

Mechanisms & Personalised Medicine

October 5, 2025

Immune checkpoint inhibitors have proven effective in selective patients with gastrointestinal and hepatobiliary cancers, but new predictive markers, combination strategies, and better management of immune-mediated side effects are needed.

KEY POINTS

- The speaker stated that search for new predictive markers of response is warranted and that the field is moving toward tumor-specific immunotypes.
- Combined approaches using immune checkpoint inhibitors plus targeted treatments, CAR-T therapy, and vaccines may represent promising strategies according to the speaker.
- Integration of gut microbiota into immunotherapy strategy should be considered and will be in the future.
- The optimal setting for immunotherapies—whether in advanced disease, adjuvant therapy, or pre-cancerous stages—deserves further study.
- Better prediction and management of immune-mediated side effects is necessary.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflrx.eu/search/d/9a06a4ce-a82e-11f0-a7f5-0242ac140006>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.